Cover Image
市場調查報告書

組蛋白去乙醯酵素2 (組蛋白去乙醯酶2) :開發中產品分析

Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 363571
出版日期 內容資訊 英文 92 Pages
訂單完成後即時交付
價格
Back to Top
組蛋白去乙醯酵素2 (組蛋白去乙醯酶2) :開發中產品分析 Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) - Pipeline Review, H1 2016
出版日期: 2016年06月22日 內容資訊: 英文 92 Pages
簡介

本報告提供組蛋白去乙醯酵素2 (組蛋白去乙醯酶2)的開發情形相關的資訊,各開發階段、藥物標的、作用機制、給藥途徑及各分子類型的分析,,開發治療藥的企業概要,最新消息和新聞稿等資訊,為您概述為以下內容。

簡介

  • 調查範圍

組蛋白去乙醯酵素2 (組蛋白去乙醯酶2)的概要

治療藥的開發

組蛋白去乙醯酵素2 (組蛋白去乙醯酶2):開發中的產品 - 各開發階段

組蛋白去乙醯酵素2 (組蛋白去乙醯酶2):開發中的產品 - 各治療範圍

組蛋白去乙醯酵素2 (組蛋白去乙醯酶2):開發中的產品 - 各適應症

組蛋白去乙醯酵素2 (組蛋白去乙醯酶2):開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

組蛋白去乙醯酵素2 (組蛋白去乙醯酶2):企業開發中的產品

組蛋白去乙醯酵素2 (組蛋白去乙醯酶2):大學/機關開發中的產品

組蛋白去乙醯酵素2 (組蛋白去乙醯酶2):治療藥的評估

  • 各單劑療法/聯合治療產品
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

組蛋白去乙醯酵素2 (組蛋白去乙醯酶2)的治療藥的開發企業

  • 4SC AG
  • Acetylon Pharmaceuticals, Inc.
  • Chipscreen Biosciences Ltd
  • Curis, Inc.
  • GlaxoSmithKline Plc
  • HitGen LTD
  • Italfarmaco S.p.A.
  • MEI Pharma, Inc.
  • Merck & Co., Inc.
  • Rodin Therapeutics
  • Sigma-Tau S.p.A.
  • TetraLogic Pharmaceuticals
  • Yungjin Pharm. Co., Ltd.

藥物簡介

組蛋白去乙醯酵素2 (組蛋白去乙醯酶2):暫停中的計劃

組蛋白去乙醯酵素2 (組蛋白去乙醯酶2):主要消息與新聞稿

附錄

目錄
Product Code: GMDHC0107TDB

Summary

Global Markets Direct's, 'Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) - Pipeline Review, H1 2016', provides in depth analysis on Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) targeted pipeline therapeutics.

The report provides comprehensive information on the Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98)
  • The report reviews Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) Overview
  • Therapeutics Development
    • Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) - Products under Development by Stage of Development
    • Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) - Products under Development by Therapy Area
    • Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) - Products under Development by Indication
  • Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) - Products under Development by Companies
  • Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) - Products under Development by Universities/Institutes
  • Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) - Companies Involved in Therapeutics Development
    • 4SC AG
    • Acetylon Pharmaceuticals, Inc.
    • Chipscreen Biosciences Ltd
    • Curis, Inc.
    • GlaxoSmithKline Plc
    • HitGen LTD
    • Italfarmaco S.p.A.
    • MEI Pharma, Inc.
    • Merck & Co., Inc.
    • Rodin Therapeutics
    • Sigma-Tau S.p.A.
    • TetraLogic Pharmaceuticals
    • Yungjin Pharm. Co., Ltd.
  • Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) - Drug Profiles
    • 4SC-202 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ACY-738 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ACY-957 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • chidamide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CS-3158 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CUDC-907 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • givinostat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HG-3001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Largazole - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • N-140 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pracinostat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • remetinostat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit HDAC2 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Histone Deacetylases for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit HDAC2 for Neurological Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ST-3595 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vorinostat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • YPL-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) - Dormant Projects
  • Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) - Featured News & Press Releases
    • Jun 08, 2016: Curis Announces Oral Presentation of Clinical Data Update from the Phase 1 Study of CUDC-907 at the 21st Congress of the European Hematology Association
    • Jun 02, 2016: Curis Announces Presentations Related to CUDC-907 at 2016 ASCO Annual Meeting
    • May 04, 2016: Acetylon Pharmaceuticals Publishes New Mechanism for the Treatment of Sickle Cell Disease/Beta-Thalassemia with Selective HDAC1/2 Inhibition in PLoS One
    • Apr 11, 2016: Curis Announces Presentation of Preclinical Data for CUDC-907 at AACR Annual Meeting
    • Apr 04, 2016: Curis Announces Publication of CUDC-907 Phase 1 Clinical Trial Data in Lancet Oncology
    • Mar 21, 2016: Epigenetic compound 4SC-202 strengthens endogenous immune response to cancer
    • Mar 03, 2016: HUYA Bioscience International Expands Senior Management Team
    • Dec 22, 2015: Huya Bioscience International Announces Orphan Drug Designation For HBI-8000 In Japan
    • Dec 07, 2015: MEI Pharma Announces Positive Results from Phase II Study of Pracinostat in Acute Myeloid Leukemia, Plans to Initiate Phase III Registration Study
    • Dec 07, 2015: Acetylon Presents Data on the Pharmacokinetics and HbE/HbG Hemoglobin Induction Following Once Daily Dosing of an Oral HDAC1,2 Inhibitor in Animal Models
    • Dec 06, 2015: Curis Reports Clinical Activity of CUDC-907 in Patients With DLBCL Harboring MYC Oncogene Alterations at the 2015 ASH Annual Meeting
    • Nov 05, 2015: Curis Announces Oral Presentation of Phase 1 Data for CUDC-907 at 2015 ASH Annual Meeting
    • Nov 02, 2015: TetraLogic Announces the Opening of an IND for SHAPE Gel in Alopecia Areata
    • Oct 06, 2015: MEI Pharma Announces Data from Phase II Clinical Studies of Pracinostat Accepted for Oral Presentation at American Society of Hematology Annual Meeting
    • Sep 30, 2015: 4SC receives funding from the Eurostars programme for further research of its anti-cancer agent 4SC-202 with an epigenetic mode of action
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Pipeline by 4SC AG, H1 2016
  • Pipeline by Acetylon Pharmaceuticals, Inc., H1 2016
  • Pipeline by Chipscreen Biosciences Ltd, H1 2016
  • Pipeline by Curis, Inc., H1 2016
  • Pipeline by GlaxoSmithKline Plc, H1 2016
  • Pipeline by HitGen LTD, H1 2016
  • Pipeline by Italfarmaco S.p.A., H1 2016
  • Pipeline by MEI Pharma, Inc., H1 2016
  • Pipeline by Merck & Co., Inc., H1 2016
  • Pipeline by Rodin Therapeutics, H1 2016
  • Pipeline by Sigma-Tau S.p.A., H1 2016
  • Pipeline by TetraLogic Pharmaceuticals, H1 2016
  • Pipeline by Yungjin Pharm. Co., Ltd., H1 2016
  • Dormant Projects, H1 2016
  • Dormant Projects (Contd..1), H1 2016
  • Dormant Projects (Contd..2), H1 2016

List of Figures

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Top 10 Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
Back to Top